These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37364001)

  • 21. Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
    Stewart CM; Michaud L; Whiting K; Nakajima R; Nichols C; De Frank S; Hamlin PA; Matasar MJ; Gerecitano JF; Drullinsky P; Hamilton A; Straus D; Horwitz SM; Kumar A; Moskowitz CH; Moskowitz A; Zelenetz AD; Rademaker J; Salles G; Seshan V; Schöder H; Younes A; Tsui DWY; Batlevi CL
    Clin Cancer Res; 2022 Jan; 28(1):45-56. PubMed ID: 34615723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.
    Jurczak W; Elmusharaf N; Fox CP; Townsend W; Paulovich AG; Whiteaker JR; Krantz F; Wun CC; Parr G; Sharma S; Munugalavadla V; Manwani R; Dean E; Munir T
    Ther Adv Hematol; 2023; 14():20406207231173489. PubMed ID: 37273420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
    Gordon LI; Karmali R; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau FI; Radford J; de Oteyza JP; Zinzani PL; Iyer SP; Townsend W; Miao H; Proscurshim I; Wang S; Katyayan S; Yuan Y; Zhu J; Stumpo K; Shou Y; Carpio C; Bosch F
    Oncotarget; 2023 Jan; 14():57-70. PubMed ID: 36702329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
    Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
    Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
    Morschhauser F; Flinn IW; Advani R; Sehn LH; Diefenbach C; Kolibaba K; Press OW; Salles G; Tilly H; Chen AI; Assouline S; Cheson BD; Dreyling M; Hagenbeek A; Zinzani PL; Jones S; Cheng J; Lu D; Penuel E; Hirata J; Wenger M; Chu YW; Sharman J
    Lancet Haematol; 2019 May; 6(5):e254-e265. PubMed ID: 30935953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Balzarotti M; Magagnoli M; Canales MÁ; Corradini P; Grande C; Sancho JM; Zaja F; Quinson AM; Belsack V; Maier D; Carlo-Stella C
    Invest New Drugs; 2021 Aug; 39(4):1028-1035. PubMed ID: 33523334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
    Sigmund AM; Denlinger N; Huang Y; Bond D; Voorhees T; Bajwa A; Elder P; Brammer JE; Saad A; Penza S; Vasu S; de Lima M; Jaglowski S; Kittai AS
    Transplant Cell Ther; 2022 Jun; 28(6):342.e1-342.e5. PubMed ID: 35248778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
    Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
    Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.
    El Bary NA; Hashem T; Metwally H; Ghany AA; El Mageed HA
    Hematol Oncol Stem Cell Ther; 2010; 3(1):13-8. PubMed ID: 20231809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Godfrey J; Mei M; Chen L; Song JY; Bedell V; Budde E; Armenian S; Puverel S; Nikolaenko L; Chen R; Daniels S; Kennedy N; Peters L; Rosen ST; Forman SJ; Popplewell LL; Kwak LW; Herrera AF
    Haematologica; 2024 Feb; 109(2):533-542. PubMed ID: 37470137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
    Herrera AF; Goy A; Mehta A; Ramchandren R; Pagel JM; Svoboda J; Guan S; Hill JS; Kwei K; Liu EA; Phillips T
    Am J Hematol; 2020 Jan; 95(1):18-27. PubMed ID: 31621094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    Strati P; Coleman M; Champion R; Ma S; Patti C; Levy MY; Lossos IS; Geethakumari PR; Lam S; Calvo R; Higgins K; Budde LE
    Br J Haematol; 2022 Oct; 199(1):76-85. PubMed ID: 35861370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
    Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
    Topp MS; Eradat H; Florschütz A; Hochhaus A; Wrobel T; Walewski J; Knopinska-Posluszny W; Kanate AS; Lech-Maranda E; Brunnberg U; Chitra S; Nielsen TG; Sellam G; Shivhare M; Lossos IS
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):811-817. PubMed ID: 35182224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
    Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
    Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
    Harrington BK; Gardner HL; Izumi R; Hamdy A; Rothbaum W; Coombes KR; Covey T; Kaptein A; Gulrajani M; Van Lith B; Krejsa C; Coss CC; Russell DS; Zhang X; Urie BK; London CA; Byrd JC; Johnson AJ; Kisseberth WC
    PLoS One; 2016; 11(7):e0159607. PubMed ID: 27434128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma.
    Shi YF; Zhou SJ; Sun L; Yu K; Chen Y
    Med Clin (Barc); 2020 Sep; 155(6):235-241. PubMed ID: 32173075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.